Applicability of Histone Deacetylase Inhibition for the Treatment of Spinal Muscular Atrophy

Overview

Journal Neurotherapeutics

Specialty Neurology

Date 2013 Sep 3

PMID 23996601

Citations 6

Authors

Sebastian Lunke

Assam El-Osta

Affiliations

Soon will be listed here.

Abstract

Spinal muscular atrophy (SMA), a neurodegenerative disease with potentially devastating and even deadly effects on affected individuals, was first described in the late nineteenth century. Although the survival of motor neuron (SMN) gene was identified nearly 2 decades ago to be causative of the disease, neither an effective treatment nor a cure are currently available. Yet efforts are on-going to test a multitude of treatment strategies with the potential to alleviate disease symptoms in human and clinical trials. Among the most studied compounds for the treatment of SMA are histone deacetylase inhibitors. Several of these epigenetic modifiers have been shown to increase expression of the crucial SMN gene in vitro and in vivo, an effect linked to increased histone acetylation and remodeling of the chromatin landscape surrounding the SMN gene promoter. Here, we review the history and current state of use of histone deacetylase inhibitors in SMA, as well as the success of clinical trials investigating the clinical applicability of these epigenetic modifiers in SMA treatment.

Citing Articles

Modeling axonal regeneration by changing cytoskeletal dynamics in stem cell-derived motor nerve organoids.

Seo W, Yoon J, Lee J, Lee Y, Lee H, Geum D Sci Rep. 2022; 12(1):2082.

PMID: 35136073 PMC: 8827082. DOI: 10.1038/s41598-022-05645-6.

New and Developing Therapies in Spinal Muscular Atrophy: From Genotype to Phenotype to Treatment and Where Do We Stand?.

Chen T Int J Mol Sci. 2020; 21(9).

PMID: 32392694 PMC: 7246502. DOI: 10.3390/ijms21093297.

Emerging roles of histone modifications and HDACs in RNA splicing.

Rahhal R, Seto E Nucleic Acids Res. 2019; 47(10):4911-4926.

PMID: 31162605 PMC: 6547430. DOI: 10.1093/nar/gkz292.

Small Molecules in Development for the Treatment of Spinal Muscular Atrophy.

Calder A, Androphy E, Hodgetts K J Med Chem. 2016; 59(22):10067-10083.

PMID: 27490705 PMC: 5744254. DOI: 10.1021/acs.jmedchem.6b00670.

Developing therapies for spinal muscular atrophy.

Wertz M, Sahin M Ann N Y Acad Sci. 2015; 1366(1):5-19.

PMID: 26173388 PMC: 4713374. DOI: 10.1111/nyas.12813.

References

Kinali M, Mercuri E, Main M, De Biasia F, Karatza A, Higgins R . Pilot trial of albuterol in spinal muscular atrophy. Neurology. 2002; 59(4):609-10. DOI: 10.1212/wnl.59.4.609. View

Coovert D, Le T, McAndrew P, Strasswimmer J, Crawford T, Mendell J . The survival motor neuron protein in spinal muscular atrophy. Hum Mol Genet. 1997; 6(8):1205-14. DOI: 10.1093/hmg/6.8.1205. View

Chang J, Hsieh-Li H, Jong Y, Wang N, Tsai C, Li H . Treatment of spinal muscular atrophy by sodium butyrate. Proc Natl Acad Sci U S A. 2001; 98(17):9808-13. PMC: 55534. DOI: 10.1073/pnas.171105098. View

Minucci S, Pelicci P . Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat Rev Cancer. 2006; 6(1):38-51. DOI: 10.1038/nrc1779. View

Velasco E, Valero C, Valero A, Moreno F, Hernandez-Chico C . Molecular analysis of the SMN and NAIP genes in Spanish spinal muscular atrophy (SMA) families and correlation between number of copies of cBCD541 and SMA phenotype. Hum Mol Genet. 1996; 5(2):257-63. DOI: 10.1093/hmg/5.2.257. View

Wirth B, Herz M, Wetter A, Moskau S, Hahnen E, Rudnik-Schoneborn S . Quantitative analysis of survival motor neuron copies: identification of subtle SMN1 mutations in patients with spinal muscular atrophy, genotype-phenotype correlation, and implications for genetic counseling. Am J Hum Genet. 1999; 64(5):1340-56. PMC: 1377870. DOI: 10.1086/302369. View

Lefebvre S, Burlet P, Liu Q, Bertrandy S, Clermont O, Munnich A . Correlation between severity and SMN protein level in spinal muscular atrophy. Nat Genet. 1997; 16(3):265-9. DOI: 10.1038/ng0797-265. View

Li B, Carey M, Workman J . The role of chromatin during transcription. Cell. 2007; 128(4):707-19. DOI: 10.1016/j.cell.2007.01.015. View

Cobben J, van der Steege G, Grootscholten P, de Visser M, Scheffer H, Buys C . Deletions of the survival motor neuron gene in unaffected siblings of patients with spinal muscular atrophy. Am J Hum Genet. 1995; 57(4):805-8. PMC: 1801497. View

10.

Brichta L, Hofmann Y, Hahnen E, Siebzehnrubl F, Raschke H, Blumcke I . Valproic acid increases the SMN2 protein level: a well-known drug as a potential therapy for spinal muscular atrophy. Hum Mol Genet. 2003; 12(19):2481-9. DOI: 10.1093/hmg/ddg256. View

11.

Madocsai C, Lim S, Geib T, Lam B, Hertel K . Correction of SMN2 Pre-mRNA splicing by antisense U7 small nuclear RNAs. Mol Ther. 2005; 12(6):1013-22. DOI: 10.1016/j.ymthe.2005.08.022. View

12.

Brichta L, Holker I, Haug K, Klockgether T, Wirth B . In vivo activation of SMN in spinal muscular atrophy carriers and patients treated with valproate. Ann Neurol. 2006; 59(6):970-5. DOI: 10.1002/ana.20836. View

13.

Melki J, Burlet P, Clermont O, Pascal F, Paul B, Abdelhak S . Refined linkage map of chromosome 5 in the region of the spinal muscular atrophy gene. Genomics. 1993; 15(3):521-4. DOI: 10.1006/geno.1993.1103. View

14.

Hastings M, Berniac J, Liu Y, Abato P, Jodelka F, Barthel L . Tetracyclines that promote SMN2 exon 7 splicing as therapeutics for spinal muscular atrophy. Sci Transl Med. 2010; 1(5):5ra12. PMC: 2818805. DOI: 10.1126/scitranslmed.3000208. View

15.

Hahnen E, Eyupoglu I, Brichta L, Haastert K, Trankle C, Siebzehnrubl F . In vitro and ex vivo evaluation of second-generation histone deacetylase inhibitors for the treatment of spinal muscular atrophy. J Neurochem. 2006; 98(1):193-202. DOI: 10.1111/j.1471-4159.2006.03868.x. View

16.

Milutinovic S, DAlessio A, Detich N, Szyf M . Valproate induces widespread epigenetic reprogramming which involves demethylation of specific genes. Carcinogenesis. 2006; 28(3):560-71. DOI: 10.1093/carcin/bgl167. View

17.

Avila A, Burnett B, Taye A, Gabanella F, Knight M, Hartenstein P . Trichostatin A increases SMN expression and survival in a mouse model of spinal muscular atrophy. J Clin Invest. 2007; 117(3):659-71. PMC: 1797603. DOI: 10.1172/JCI29562. View

18.

Brahe C, Vitali T, Tiziano F, Angelozzi C, Pinto A, Borgo F . Phenylbutyrate increases SMN gene expression in spinal muscular atrophy patients. Eur J Hum Genet. 2004; 13(2):256-9. DOI: 10.1038/sj.ejhg.5201320. View

19.

Wlodarczyk B, Craig J, Bennett G, Calvin J, Finnell R . Valproic acid-induced changes in gene expression during neurulation in a mouse model. Teratology. 1996; 54(6):284-97. DOI: 10.1002/(SICI)1096-9926(199612)54:6<284::AID-TERA3>3.0.CO;2-Z. View

20.

Valori C, Ning K, Wyles M, Mead R, Grierson A, Shaw P . Systemic delivery of scAAV9 expressing SMN prolongs survival in a model of spinal muscular atrophy. Sci Transl Med. 2010; 2(35):35ra42. DOI: 10.1126/scitranslmed.3000830. View